124 related articles for article (PubMed ID: 24536077)
1. Biomarkers and response to bevacizumab--response.
Collinson F; Hutchinson M; Craven RA; Cairns DA; Alexandre Z; Wind TC; Gahir N; Messenger MP; Jackson S; Thompson D; Adusei C; Ledermann J; Hall G; Jayson GC; Selby PJ; Banks RE
Clin Cancer Res; 2014 Feb; 20(4):1058. PubMed ID: 24536077
[No Abstract] [Full Text] [Related]
2. Biomarkers and response to bevacizumab--letter.
Cremolini C; Loupakis F; Bocci G; Falcone A
Clin Cancer Res; 2014 Feb; 20(4):1056-7. PubMed ID: 24536076
[No Abstract] [Full Text] [Related]
3. Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection.
Collinson F; Hutchinson M; Craven RA; Cairns DA; Zougman A; Wind TC; Gahir N; Messenger MP; Jackson S; Thompson D; Adusei C; Ledermann JA; Hall G; Jayson GC; Selby PJ; Banks RE
Clin Cancer Res; 2013 Sep; 19(18):5227-39. PubMed ID: 23935036
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab in ovarian cancer: unanswered questions.
Muggia F
Drugs; 2012 May; 72(7):931-6. PubMed ID: 22564133
[No Abstract] [Full Text] [Related]
5. Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers.
Dao MD; Alwan LM; Gray HJ; Tamimi HK; Goff BA; Liao JB
Gynecol Oncol; 2013 Aug; 130(2):295-9. PubMed ID: 23632207
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
Nimeiri HS; Oza AM; Morgan RJ; Friberg G; Kasza K; Faoro L; Salgia R; Stadler WM; Vokes EE; Fleming GF; ; ;
Gynecol Oncol; 2008 Jul; 110(1):49-55. PubMed ID: 18423560
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Dhillon S
BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of serum HE4 in patients with advanced ovarian, fallopian tube, and peritoneal carcinoma.
Mi D; Zhang Y
Arch Gynecol Obstet; 2020 Mar; 301(3):779-785. PubMed ID: 32034508
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab combination therapy: for the first-line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.
Dhillon S
Drugs; 2012 May; 72(7):917-30. PubMed ID: 22515620
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
Secord AA; McCollum M; Davidson BA; Broadwater G; Squatrito R; Havrilesky LJ; Gabel AC; Starr MD; Brady JC; Nixon AB; Duska LR
Gynecol Oncol; 2019 Jun; 153(3):555-561. PubMed ID: 30929823
[TBL] [Abstract][Full Text] [Related]
11. Tumour markers, ultrasonography, and ovarian cancer diagnosis.
Murta EF
Eur J Gynaecol Oncol; 2014; 35(2):111. PubMed ID: 24772908
[No Abstract] [Full Text] [Related]
12. What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies?
Cheng X; Moroney JW; Levenback CF; Fu S; Jaishuen A; Kavanagh JJ
J Chemother; 2009 Nov; 21(5):566-72. PubMed ID: 19933049
[TBL] [Abstract][Full Text] [Related]
13. Reply from M. Bozkurt, A E. Yumru1, I. Aral.
Bozkurt M
Eur J Gynaecol Oncol; 2014; 35(2):111-2. PubMed ID: 24772909
[No Abstract] [Full Text] [Related]
14. Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial.
Randall LM; Sill MW; Burger RA; Monk BJ; Buening B; Sorosky JI
Gynecol Oncol; 2012 Mar; 124(3):563-8. PubMed ID: 22138229
[TBL] [Abstract][Full Text] [Related]
15. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.
Roque DM; Ratner ES; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Nelson WK; Santin AD
Gynecol Oncol; 2015 Jun; 137(3):392-400. PubMed ID: 25792179
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response.
Levy T; Weiser R; Boaz M; Shem EB; Golan A; Menczer J
Int J Gynecol Cancer; 2012 Oct; 22(8):1344-8. PubMed ID: 22954785
[TBL] [Abstract][Full Text] [Related]
17. A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.
Nakanishi T; Aoki D; Watanabe Y; Ando Y; Tomotsugu N; Sato Y; Saito T
Jpn J Clin Oncol; 2015 May; 45(5):422-6. PubMed ID: 25670764
[TBL] [Abstract][Full Text] [Related]
18. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.
Han ES; Burger RA; Darcy KM; Sill MW; Randall LM; Chase D; Parmakhtiar B; Monk BJ; Greer BE; Connelly P; Degeest K; Fruehauf JP
Gynecol Oncol; 2010 Dec; 119(3):484-90. PubMed ID: 20870280
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma.
Arora N; Tewari D; Cowan C; Saffari B; Monk BJ; Burger RA
Int J Gynecol Cancer; 2008; 18(2):369-72. PubMed ID: 17624986
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study.
Hurteau JA; Brady MF; Darcy KM; McGuire WP; Edmonds P; Pearl ML; Ivanov I; Tewari KS; Mannel RS; Zanotti K; Benbrook DM
Gynecol Oncol; 2010 Dec; 119(3):444-50. PubMed ID: 20846715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
